Stevanato Group S.p.A., a global provider of drug containment, delivery, and diagnostic solutions, reported an 8% increase in revenue for the second quarter of 2025, reaching €280.0 million. This growth was primarily driven by a 10% increase in the Biopharmaceutical and Diagnostic Solutions segment, which offset a 2% decline in the Engineering Segment. High-value solutions contributed to €116.8 million of total revenue, representing 42% of the quarter's revenue, bolstered by strong demand for high-value syringes and EZ-fill® products. The company also reported a gross profit margin increase of 210 basis points to 28.1% and an adjusted EBITDA margin increase of 240 basis points to 23.2%. Diluted earnings per share and adjusted diluted earnings per share were both reported at €0.11. Stevanato Group is maintaining its fiscal 2025 guidance, expecting revenue between €1.160 billion and €1.190 billion, adjusted EBITDA from €288.5 million to €301.8 million, and adjusted diluted EPS ranging from €0.50 to €0.54. The company believes it has adequate liquidity to support its strategic priorities over the next twelve months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.